Kanvas Biosciences Secures $48M Series A to Deliver Novel Microbiome Therapeutics to Cancer Patients

Kanvas生物科学公司获得4800万美元A轮融资，用于向癌症患者提供新型微生物组疗法

The investment round, which includes Gates Foundation, will advance Kanvas’ lead immuno-oncology drug that seeks to improve the efficacy of immunotherapy in the treatment of solid organ cancers.

包括盖茨基金会在内的这轮投资将推动Kanvas领先的免疫肿瘤药物，该药物旨在提高免疫疗法在治疗实体器官癌症方面的疗效。

PRINCETON, N.J., May 6, 2026-- Kanvas Biosciences, a full-stack spatial biology company, today announced it has raised a $48 million Series A funding round co-led by existing investors DCVC and Lions Capital LLC. Additional participating investors include Gates Foundation, ATHOS KG, Germin8, Ki Tua Fund, Pangaea Ventures and more.

普林斯顿，新泽西州，2026年5月6日 —— 全栈空间生物学公司Kanvas Biosciences今日宣布，已完成由现有投资者DCVC和Lions Capital LLC共同领投的4800万美元A轮融资。其他参与投资的机构包括盖茨基金会、ATHOS KG、Germin8、Ki Tua基金、Pangaea Ventures等。

The fresh capital follows a July 2024 round and brings Kanvas’ total funding to $78 million. The funding will be used to conduct clinical trials for the lead drug candidate in the company’s immuno-oncology program, KAN-001, and advance commercial partnerships that leverage Kanvas’ spatial imaging and manufacturing platform for next generation live biotherapeutic product (LBP) development..

这笔新资金继 2024 年 7 月一轮融资之后，使 Kanvas 的总融资额达到 7800 万美元。这笔资金将用于为其免疫肿瘤学项目中的主要候选药物 KAN-001 进行临床试验，并推动利用 Kanvas 的空间成像和制造平台开发下一代活体生物治疗产品 (LBP) 的商业合作。

A microbiome is a collection of microorganisms and their genes that live in the gut, lungs, on skin and in other tissue. Malfunctioning microbiomes can lead to inflammatory bowel disease, celiac disease, cardiovascular problems and even impact how cancer patients respond to immunotherapy. Kanvas has developed the unique ability to spatially map microbial cells and host cells, which allows the company to manufacture LBPs made of complex consortia containing hundreds of members that can restore microbiome health, and clearly visualize LBP engraftment and activity – two longstanding roadblocks in the quest to develop effective therapeutics for restoring the microbiome..

微生物组是生活在肠道、肺部、皮肤及其他组织中的微生物及其基因的集合。功能失调的微生物组可能导致炎症性肠病、乳糜泻、心血管问题，甚至影响癌症患者对免疫疗法的反应。Kanvas 开发出了一种独特的能力，可以对微生物细胞和宿主细胞进行空间定位，这使得该公司能够制造由包含数百个成员的复杂菌群组成的活体生物治疗产品（LBP），从而恢复微生物组健康，并清晰地可视化 LBP 的植入和活性——这是开发有效恢复微生物组疗法过程中长期存在的两大障碍。

Clinical Applications and Development Pathway

临床应用与发展路径

KAN-001 is a LBP designed for cancer patients who don't respond to immune checkpoint inhibitors (ICIs). While over 50% of solid organ cancer patients receive ICIs, only 10% achieve complete responses. Fecal microbiota transplants (FMT) from ICI responders can convert non-responders into responders, but they pose manufacturing challenges, pathogen risks and scalability issues.

KAN-001 是一种专为对免疫检查点抑制剂 (ICIs) 无反应的癌症患者设计的LBP。尽管超过50%的实体癌患者接受ICIs治疗，但只有10%能达到完全缓解。来自ICI有反应者的粪便微生物移植 (FMT) 可以将无反应者转化为有反应者，但其存在生产挑战、病原体风险和可扩展性问题。

KAN-001 addresses these limitations, and has demonstrated safety and efficacy across multiple mouse models and tumor types. Importantly, the clinical pathway has been substantially de-risked: In a recent FMT trial for anti-PD-1 refractory microsatellite instability high cancers, fecal material from the same donor from which the specific KAN-001 strains were isolated was delivered to study participants via FMT.

KAN-001 解决了这些局限性，并在多种小鼠模型和肿瘤类型中展示了安全性和有效性。重要的是，临床路径的风险已大大降低：在最近一项针对抗PD-1难治性高微卫星不稳定性癌症的FMT试验中，从分离出特定KAN-001菌株的同一捐赠者中提取的粪便材料通过FMT传递给了研究参与者。

Results showed high engraftment rates, restored anti-PD-1 response and no ICI-induced colitis. Kanvas will now launch its own clinical trials and operationalize its newly opened GMP manufacturing suite..

结果显示，移植率高，恢复了抗PD-1反应，且没有ICI诱导的结肠炎。Kanvas现在将启动自己的临床试验，并将其新开设的GMP制造套件投入运营。

“I began my career as a physician and always dreamed of being able to develop new drugs that could help the patients I hadn’t been able to treat with existing therapies,” said Matthew Cheng, co-founder and CEO of Kanvas Biosciences. “Most physicians never get the opportunity to realize this dream, so it’s an incredible privilege to bring Kanvas’ technology to the broader LBP market and begin conducting clinical trials of our lead drug candidate, which offers a new way to improve the therapeutic efficacy and safety of immunotherapy for cancer patients.”.

“我以医生的身份开始了我的职业生涯，一直梦想着能够开发出帮助那些现有疗法无法治疗的患者的新药，”Kanvas生物科学公司的联合创始人兼首席执行官Matthew Cheng说。“大多数医生从来没有机会实现这个梦想，所以能够将Kanvas的技术带到更广泛的LBP市场，并开始对我们主要的候选药物进行临床试验，这是一种难以置信的荣幸。这种药物为提高癌症患者免疫治疗的疗效和安全性提供了一种新方法。”

Recent Company Momentum

公司近期发展势头

Since announcing its Seed round in 2024, Kanvas has made significant progress. Recent milestones include:

自 2024 年宣布其种子轮融资以来，Kanvas 取得了显著的进展。近期的里程碑包括：

• Investment from Gates Foundation: With new funding from Gates Foundation and other investors, Kanvas is developing the world’s first fully synthetic microbiome replacement product designed to treat and prevent maternal environmental enteric dysfunction, a major contributor to maternal undernutrition, low infant birthweight and heightened neonatal health risk..

• 盖茨基金会投资：通过盖茨基金会及其他投资者的新一轮资金支持，Kanvas公司正在开发全球首款完全合成的微生物组替代产品，旨在治疗和预防孕产妇环境性肠功能障碍。该疾病是导致孕产妇营养不良、婴儿出生体重偏低以及新生儿健康风险增加的主要因素之一。

• Clinical Trial: Preparations for patient recruitment are underway for a Phase 1 clinical trial of KAN-004, Kanvas’ immuno-oncology drug candidate that targets ICI-induced colitis and may allow cancer patients to stay on ICI therapy longer with improved response rates.

• 临床试验：Kanvas的免疫肿瘤药物候选物KAN-004的1期临床试验的患者招募准备工作正在进行中，该药物针对ICI诱发的结肠炎，可能使癌症患者能够更长时间地接受ICI治疗，并提高反应率。

• Board Additions: Stephen Quake, the Lee Otterson Professor of Bioengineering and Professor of Applied Physics at Stanford University and former Chief Science Advisor for the Chan Zuckerberg Initiative, joined Kanvas’ Board.

• 董事会新增成员：Stephen Quake，斯坦福大学生物工程与应用物理教授，曾担任陈-扎克伯格倡议的首席科学顾问，已加入Kanvas董事会。

• New Research: Kanvas recently unveiled new research that demonstrates how the company’s spatial imaging platform outperforms gold standard methods such as metagenomics sequencing, especially in low biomass settings.

• 新研究：Kanvas 近期公布了一项新研究，展示了其空间成像平台在性能上优于宏基因组测序等黄金标准方法，尤其是在低生物量环境中的表现。

• Novel Lightsheet Microscope: The company has developed the Kanvas Spectral Lightsheet, a high-resolution, multispectral lightsheet microscope that generates vastly more spatial biology data to train Kanvas’ AI platform and build the world's first microbiome atlas.

新型光片显微镜：该公司开发了Kanvas光谱光片显微镜，这是一种高分辨率、多光谱的光片显微镜，能够生成更多的空间生物学数据，用于训练Kanvas的人工智能平台，并构建世界上首个微生物组图谱。

“Creating a brand new microscope capable of collecting spatial biology data at unprecedented scale and quality is a testament to Kanvas’ deep engineering prowess and relentless commitment to unlocking the gut microbiome as a distinct organ that can be safely modified using microbial-based drugs,” said Jason Pontin, General Partner at DCVC and chair of Kanvas’ board.

“创造一个能够以前所未有的规模和质量收集空间生物学数据的全新显微镜，证明了Kanvas深厚的工程实力以及其不懈致力于将肠道微生物组视为一个独特器官，并利用基于微生物的药物进行安全改造的决心，”DCVC的普通合伙人兼Kanvas董事会主席Jason Pontin表示。

“Kanvas’ ability to generate novel data about host-microbiome interactions is fueling powerful AI models that are helping the company design new cancer treatments, nutritional supplements and even gastrointestinal restoration products for animals.”.

“Kanvas生成关于宿主-微生物组相互作用的新数据的能力，正在推动强大的人工智能模型，这些模型帮助公司设计新的癌症治疗方法、营养补充剂，甚至是动物的胃肠道修复产品。”

Additional investors in Kanvas’ Series A include Alumni Ventures, Boutique Venture Partners, Cornell University, FemHealth Ventures, Gaingels, Mana Ventures, Red Bear Ventures, RIT Venture Fund, Triple Impact Capital, Kicker Ventures and Uncommon Denominator. For more information on Kanvas or to inquire about clinical trial site opportunities and/or LBP development partnerships, visit https://www.kanvasbio.com/..

参与 Kanvas A 轮投资的其他投资者包括 Alumni Ventures、Boutique Venture Partners、康奈尔大学、FemHealth Ventures、Gaingels、Mana Ventures、Red Bear Ventures、RIT Venture Fund、Triple Impact Capital、Kicker Ventures 和 Uncommon Denominator。如需了解有关 Kanvas 的更多信息，或咨询临床试验站点合作机会和/或 LBP 开发合作伙伴关系，请访问 https://www.kanvasbio.com/。

About Kanvas Biosciences

关于Kanvas生物科学

Kanvas Biosciences is a spatial biology company building the world’s first microbiome drug screening, discovery and manufacturing platform to accelerate the development of next generation live biotherapeutics. With an unparalleled ability to spatially map the microbiome and profile host gene expression, and manufacture complex consortia containing hundreds of members that can restore microbiome health, the company is uniquely positioned to develop novel therapeutics that can significantly improve the lives of all patients living with microbiome-associated diseases.

Kanvas Biosciences 是一家空间生物学公司，正在构建世界上首个微生物组药物筛选、发现和制造平台，以加速下一代活体生物治疗药物的开发。凭借无与伦比的空间微生物组测绘能力、宿主基因表达谱分析能力，以及制造包含数百种成员的复杂菌群以恢复微生物组健康的能力，该公司在开发能够显著改善所有患有微生物组相关疾病患者生活的新型疗法方面具有独特优势。

Kanvas Biosciences' technology was initially developed at Cornell University and exclusively licensed. The company's notable investors include DCVC, Lions Capital LLC, Gates Foundation, ATHOS KG, FemHealth Ventures, Germin8, Ki Tua Fund, Pangaea Ventures, Triple Impact Capital and Uncommon Denominator.

Kanvas Biosciences的技术最初在康奈尔大学开发，并获得了独家授权。该公司著名的投资者包括DCVC、Lions Capital LLC、盖茨基金会、ATHOS KG、FemHealth Ventures、Germin8、Ki Tua Fund、Pangaea Ventures、Triple Impact Capital和Uncommon Denominator。

Kanvas Biosciences is headquartered in Princeton, NJ. For more information, visit www.kanvasbio.com or follow the company on LinkedIn..

Kanvas Biosciences 总部位于新泽西州普林斯顿。欲了解更多信息，请访问 www.kanvasbio.com 或在 LinkedIn 上关注该公司。

Contact:

联系人：

Media Contact

媒体联系人

Kerry Walker

克里·沃克

kerry@walkercomms.com

克里@沃克通信.com